Genitourinary Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner
Emily Lemke, DNP, AGPCNP-BC, AOCNP®
J Adv Pract Oncol 2022;13(6):596-602 |
© 2022 Harborside™
Emily Lemke, DNP, AGPCNP-BC, AOCNP®, of the Medical College of Wisconsin Cancer Center, comments on MET and CTLA-4 inhibitors for clear cell renal cell carcinoma, maintenance targeted therapy for patients with metastatic urothelial carcinoma, the landscape of metastatic hormone-sensitive prostate cancer, a consensus definition for platinum ineligibility, and PSMA-positive metastatic castration-resistant prostate cancer.
For access to the full length article, please sign in